Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06364176
Status:
RECRUITING
Last Update Posted:
2024-06-05
First Post:
2024-03-06
Brief Title:
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
Sponsor:
University of Kansas Medical Center
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis CF on modulator therapy The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator CFTR channel to modulator therapy
Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function
Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function
Detailed Description:
This is a randomized placebo-controlled parallel group clinical trial in those those with CF on elexacaftortezacaftorivacaftor to determine if treatment with losartan improves response to modulator therapy using sweat chloride as an marker of CFTR function
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None